Kiran Mazumdar-Shaw says Biocon’s integration of Biocon Biologics and entry of Serum Institute and Viatris will not alter its strategy, aiming to build a unique global biopharma enterprise.
Kiran Mazumdar-Shaw says Biocon’s integration of Biocon Biologics and entry of Serum Institute and Viatris will not alter its strategy, aiming to build a unique global biopharma enterprise.